Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study By admin / 09/24/2025
Real world clinical experience from ENABLE, the first Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab By admin / 09/24/2025
Long-Term Efficacy and Safety of Ublituximab in Relapsing Multiple Sclerosis: Results from 6 Years of ULTIMATE I and II Open-Label By admin / 09/24/2025
Safety and Tolerability of 30-minute Ublituximab Infusions: Updates from the ENHANCE Study By admin / 05/29/2025
Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) By admin / 05/29/2025
No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long term ublituximab (UBL) treatment in patients with Relapsing Multiple Sclerosis (RMS) By admin / 05/29/2025
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the OpenLabel Extension of ULTIMATE I and II Studies By admin / 04/09/2025
Safety and Tolerability of a Modified Dosing Regimen of Ublituximab: Updates from the ENHANCE Study By admin / 04/09/2025
No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS) By admin / 04/07/2025
ENABLE: the first phase 4 observational study for patients with relapsing MS treated with ublituximab in real world clinical settings By admin / 04/07/2025
